Key result
IKur and IKACh channels are promising targets for new rhythm control drugs in the downstream approach to atrial fibrillation, potentially offering atrial-selective effects with fewer ventricular side effects.
Development of atrial-selective antiarrhythmic drugs targeting IKur and IKACh may provide safer rhythm control options for atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Toru Yamashita (2010) conducted a review in Atrial fibrillation. Downstream approaches (IKur and IKACh channel blockers) was evaluated. IKur and IKACh channels are promising targets for new rhythm control drugs in the downstream approach to atrial fibrillation, potentially offering atrial-selective effects with fewer ventricular side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: